Cramer's Morning Take: Microsoft & Viking Therapeutics 3/26/24

Jim Cramer (0:01)

Jim Cramer here to share with you a sample of my take on the market from today's CNBC Investing Club morning meeting.

Jeff Marks (0:08)

Just to get back to some market stories, there was a price target increase on Wedbush, a big focus on Copilot.

Based on their checks, they think momentum is building around Copilot adoption. That's the AI tool that you can use.

Jim Cramer (0:22)

Remember when someone came out of 470 and said it's not being used?

Jeff Marks (0:28)

I think the story was in the Wall Street Journal about perhaps maybe it's not worth the price.

Jim Cramer (0:32)

But there's going to be a button on your PC.

Jeff Marks (0:35)

Right. That was the big thing last week. Microsoft, they've revealed their new Surface Pro X and Laptop 6 that have that dedicated Copilot feature that essentially makes it.

You can use generative AI applications very seamlessly with that.

Jim Cramer (0:50)

This is where people were making this judgment that it's not like. Now, I will tell you that versus Cloud 3, I think Cloud 3 is superior. Cloud 3 is pros and this one, CHAT GP is a little more robotic, but you get the right answers for the most part.

Jeff Marks (1:07)

Yeah. Well, I think the big takeaway here from the web bush node at least is that, obviously Microsoft has a massive installed base. They think 70 percent of that will adopt Copilot, which will obviously be huge for revenues.

Jim Cramer (1:22)

Oh, yeah. I mean, I think that people have to understand that Microsoft also has no problem with the Justice Department. They went after them in 2000, they've not gone after them this time.

It's surprising that they haven't given the fact that they're so powerful. But what a performer. Now, we can't have a day without talking about the obesity space. By the way, Larry Fink tonight talks about the obesity space and how important it is for people to be living longer. He's basically saying these are the drugs that will extend your life.

So obviously, this Viking Therapeutics keeps coming back as being something that is a threat to Eli Lilly. This time, it's because of a pill that is more efficacious, at least in phase one.

Jeff Marks (2:03)

Yeah, it's phase one data. Hard to make an apples to apples comparison. So its data showed a 5.3% weight loss reduction at 28 days, so four weeks. Well, Lilly's, I mean, they're further ahead, phase two. But it showed 14.7% mean weight reduction at 36 weeks. So we're on a different scale here.

But look, and keep in mind also that Eli Lilly already investing in manufacturing capacity for the pill ahead of phase three, ahead of potential FDA approval, because they are so confident in that opportunity.

Jim Cramer (2:36)

Join the CNBC Investing Club with Jim Cramer to catch my member exclusive warning minis every day at 10, 20 a.m.

Visit cnbc.com/morningtake to become a member today. That's one word, morning take.

SPEAKER_3 (2:54)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBC Universal or their parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium.

No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club Disclaimer, please visit cnbc.com forward slash investing club disclaimer.